Cholesterol Management Program
BMS Clinic offers an advanced Cholesterol Management Program designed for individuals with elevated cholesterol levels or increased cardiovascular risk.
Through precision-based approaches, the program supports LDL-C reduction and helps maintain overall cardiovascular health.
BMS Clinic offers an advanced Cholesterol Management Program designed for individuals with elevated cholesterol levels or increased cardiovascular risk. Through precision-based approaches, the program supports effective LDL-C reduction and helps lower the risk of atherosclerosis, heart disease, and stroke. By integrating advanced medical technologies with personalized care, we provide a safe, long-term, and convenient solution to support your cardiovascular health.
Key Focus Areas in Cardiovascular Risk Management
With the influence of lifestyle and metabolic factors, some individuals may experience imbalances in cholesterol levels, which can increase vascular burden and impact overall cardiovascular health.
BMS Clinic provides a structured Cholesterol Management Program, integrating advanced technologies with personalized assessment to support lipid balance and help maintain a more stable cardiovascular condition.
Common Conditions We Focus On Include:
• Persistently elevated low-density lipoprotein cholesterol (LDL-C)
• Unstable lipid levels or values not within optimal range
• Increased vascular burden affecting circulatory health
• Combined metabolic risk factors (e.g. blood glucose and blood pressure fluctuations)
• Long-term accumulation of cardiovascular risk factors
Mechanism of Action
This advanced therapy uses a targeted approach at the cellular level in the liver, focusing on specific genetic pathways to regulate the overproduction of the PCSK9 protein. PCSK9 normally promotes the degradation of LDL receptors on liver cells; when PCSK9 activity is inhibited, more LDL receptors are preserved on the liver surface, significantly enhancing the clearance of low-density lipoprotein cholesterol (LDL-C) from the bloodstream.
Clinical studies suggest that this approach may achieve a sustained LDL-C reduction of approximately 45–55%, with long-lasting effects supported by a maintenance dosing schedule of once every 6 months, complementing traditional daily oral lipid-lowering therapies.
Long-Acting Control
Maintenance injection required only once every 6 months
Reducing the need for daily medication
Clinically Supported
May achieve LDL-C reduction of approximately 45–55%
(Based on ORION studies and related clinical research)
In-Clinic Administration
Performed by a registered physician in a clinical setting
The procedure takes only a few minutes, offering a safe and convenient experience
Who Is This Program Suitable For?
- Individuals diagnosed with familial hypercholesterolemia (HeFH) or atherosclerotic cardiovascular disease (ASCVD)
- Those who have not achieved LDL-C targets despite maximum-dose statins or other lipid-lowering therapies
- Individuals with statin intolerance or significant side effects
- People with elevated cardiovascular risk (e.g. diabetes, hypertension, smoking history, family history)
When Should You Consider This Program?
When LDL-C levels remain persistently elevated, standard treatments are insufficient, or when a reduction in daily medication burden and more stable long-term control is desired, this program may be considered. Physicians will provide recommendations based on lipid profiles and cardiovascular risk assessment.
Pre-Assessment & Target Levels
Required Tests:
Comprehensive lipid profile (Lipid Profile), liver and kidney function tests (Liver & Kidney Function)
Reference LDL-C Targets:
- General high risk: <70 mg/dL (<1.8 mmol/L)
- Very high risk: <55 mg/dL (<1.4 mmol/L) or ≥50% reduction from baseline
Program Journey
Important Considerations & Potential Risks
This therapy is generally well tolerated, with a favorable safety profile. The most commonly reported side effects are mild and may include redness, swelling, pain, or itching at the injection site, which typically resolve spontaneously within a few days.
Serious adverse reactions are considered very rare.
Important Notes:
- Not suitable for individuals who are pregnant, planning pregnancy, or breastfeeding
- Individuals with severe liver or kidney impairment require special evaluation
- Regular monitoring of lipid levels is recommended throughout the program
At BMS Clinic, all treatments are conducted under the supervision of registered physicians. A comprehensive pre-treatment screening is performed, and coordination with your primary cardiologist can be arranged to ensure compatibility with existing therapies.
Medical Disclaimer:
The information provided in this article is for educational and reference purposes only and does not constitute medical advice or be used as a substitute for professional medical diagnosis, treatment, or advice. ALWAYS CONSULT ANY QUESTIONS YOU MAY HAVE ABOUT YOUR MEDICAL CONDITION OR MEDICAL PROBLEM THAT YOU HAVE ALWAYS CONSULT YOUR PHYSICIAN OR OTHER QUALIFIED HEALTH PROFESSIONAL. The content of this article is not intended to recommend any specific test, treatment, or medication and should not be construed as such. If you develop symptoms or require medical assistance, please contact a healthcare professional promptly.
References
- Zhang Y, et al. Inclisiran: a new generation of lipid-lowering siRNA therapeutic. *Front Pharmacol*. 2023. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1260921/full
- Wang N, et al. A new approach to PCSK9 therapeutics. *Trends Cardiovasc Med*. 2018. https://pmc.ncbi.nlm.nih.gov/articles/PMC5848492/
- Ray KK, et al. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol (ORION-10 & ORION-11). *N Engl J Med*. 2020. https://www.nejm.org/doi/full/10.1056/NEJMoa1912387
- Raal FJ, et al. Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia (ORION-9). *N Engl J Med*. 2020. https://www.nejm.org/doi/full/10.1056/NEJMoa1913805
- Mach F, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias. *Eur Heart J*. 2020. https://academic.oup.com/eurheartj/article/41/1/111/5556353
- Wright RS, et al. Effects of Inclisiran in Patients With Atherosclerotic Cardiovascular Disease (pooled ORION-10/11 analysis). *Mayo Clin Proc*. 2024. https://www.mayoclinicproceedings.org/article/S0025-6196(24)00167-8/fulltext